NCT00295828已完成1 期
A Pilot Study for the Treatment of Iris Neovascularization With Macugen
Hermann Eye Center2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2006年1月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Regression of iris neovascularization and prevention of development of neovascular glaucoma
研究概览
简要总结
The purpose of this study is to determine if a drug called Macugen may help to stop the growth of abnormal blood vessels on the iris that has occurred in the eye(s) as part of diabetic retinopathy.
详细描述
Diabetic retinopathy is an eye condition caused by diabetes in which new blood vessels grow on the retina (the back, inside part of the eye) and the iris. These vessels are not normal and may leak or break, causing bleeding in the eye. This process can lead to vision loss or blindness, glaucoma (disease of the eye where eye pressures are usually too high resulting in damage to the optic nerve), or other eye problems. This study is to determine if a drug called Macugen may help to stop the growth of these abnormal blood vessels on the iris.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female, at least 18 years of age
- •Diabetic retinopathy with iris neovascularization
- •Visual acuity must be light perception or better in the study eye
- •Female patients of childbearing potential must have a negative urine pregnancy test at the screening visit.
- •Written informed consent has been obtained
- •Written authorization for use and release of health and research study information has been obtained
排除标准
- •Neovascular glaucoma ( a difficult form of glaucoma to control that leads to a painful eye with high intraocular pressure, corneal swelling, and "cell and flare" in the anterior chamber. Caused by abnormal new blood vessel formation (neovascularization) on the iris, that extends over trabecular meshwork causing closure of angle drainage structures).
- •No light perception in the study eye.
- •Inadequate view of retina for PRP/angiography
- •Anterior chamber intraocular lens implant
- •PRP treatment in the past 60 days. Patients may participate if the PRP treatment is beyond 60 days and has newly diagnosed NVI or has nonregression of previously diagnosed NVI.
- •Previous or current Macugen use
- •Any active ocular infection
- •Any conditions which precludes patients ability to comply with study requirements including completion of the study
- •Female patients who are pregnant, nursing, or planning pregnancy, or who are of childbearing potential and not using a reliable means of contraception
- •Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to screening
- •Patient has a condition or is in a situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results or may interfere significantly with the patient's participation in the study
结局指标
主要结局
Regression of iris neovascularization and prevention of development of neovascular glaucoma
时间窗: prospective
次要结局
- Iris angiogram - conducted at screening/treatment visit,week 1, week 3, week 6, week 9, week 12, week 15, week 18, and week 52.(prospective)
- Regression will be determined by lack of leakage and/or lack of flow through the abnormal vessels.(prospective)
- Assessment of retina with dilated fundus examination for signs of neovascularization in posterior segment at each follow-up visit(prospective)
- The complete resolution of iris neovascularization, or regression to less than 2 clock hours of iris neovascularization.(prospective)
- A clinically significant reduction in the clock hours of angle neovascularization.(prospective)
- Development of neovascular glaucoma.(prospective)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
3 期
Subretinal Macugen® for Neovascular Age-Related Macular DegenerationAge-related Macular DegenerationNCT00788177Klinikum Ludwigshafen10
已完成
2 期
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)Macular DegenerationNCT00087763Eyetech Pharmaceuticals135
已完成
2 期
Subconjunctival Bevacizumab and Recurrent PterygiumRecurrent PterygiumNCT01744756Instituto de Olhos de Goiania36
已完成
2 期
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.Macular Edema Associated With Diabetes MellitusNCT00605280Pfizer317
已完成
不适用
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.Neovascular Age-related Macular DegenerationNCT00549055Pfizer38